Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The aim of this study is to support development of asciminib in the pediatric population (1 to \< 18 years) with Ph+ CML-CP. The study will evaluate the efficacy and safety of asciminib in pediatric formulation (weigh-based dose, fed state) or adult formulation (fasted) in newly diagnosed and resistant or intolerant Ph+ CML-CP with or without T315I mutation.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek od 1 do poniżej 18 lat
- •Rozpoznana białaczka szpikowa z chromosomem Philadelphia
- •Nowo rozpoznana choroba (w ciągu 3 miesięcy) lub choroba oporna na wcześniejsze leczenie
- •Potwierdzony typ genu BCR::ABL1 do standardowych badań
- •Wymagana zgoda rodziców/opiekunów na udział w badaniu
Simplified criteria — AI translation
Trial details
- Minimum age
- 1 Year
- Maximum age
- 18 Years
- Last updated (source)
- July 24, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (24)
Rutgers Cancer Institute of New Jersey
New Brunswick, United States
Columbia University Medical Center New York Presbyterian
New York, United States
Seattle Childrens Hospital
Seattle, United States
Novartis Investigative Site
Brisbane, Australia
Novartis Investigative Site
North Adelaide, Australia
Novartis Investigative Site
Edmonton, Canada
Novartis Investigative Site
Montreal, Canada
Novartis Investigative Site
Zhengzhou, China
Novartis Investigative Site
Tianjin, China
Novartis Investigative Site
Marseille, France
Novartis Investigative Site
Paris, France
Novartis Investigative Site
Poitiers, France
Novartis Investigative Site
Strasbourg, France
Novartis Investigative Site
Roma, Italy
Novartis Investigative Site
Yokohama, Japan
Novartis Investigative Site
Fukuoka, Japan
Novartis Investigative Site
Saitama, Japan
Novartis Investigative Site
Utrecht, Netherlands
Novartis Investigative Site
Gdansk, Poland
Novartis Investigative Site
Wroclaw, Poland
Novartis Investigative Site
Seoul, South Korea
Novartis Investigative Site
Seoul, South Korea
Novartis Investigative Site
Barcelona, Spain
Novartis Investigative Site
Madrid, Spain
Trial contact
Novartis Pharmaceuticals
Novartis Pharmaceuticals
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/10/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.